Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: doody r. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials.
Quattrone A, Franzmeier N, Huppertz HJ, Klietz M, Roemer SN, Boxer AL, Levin J, Höglinger GU; AL‐108‐231 Investigators, the Tauros MRI Investigators, the PASSPORT Study Group, the DESCRIBE‐PSP Group. Quattrone A, et al. Mov Disord. 2024 Aug;39(8):1329-1342. doi: 10.1002/mds.29866. Epub 2024 Jun 2. Mov Disord. 2024. PMID: 38825840
Robust, fully-automated assessment of cerebral perivascular spaces and white matter lesions: a multicentre MRI longitudinal study of their evolution and association with risk of dementia and accelerated brain atrophy.
Barisano G, Iv M, Choupan J, Hayden-Gephart M; Alzheimer’s Disease Neuroimaging Initiative. Barisano G, et al. EBioMedicine. 2024 Dec 24;111:105523. doi: 10.1016/j.ebiom.2024.105523. Online ahead of print. EBioMedicine. 2024. PMID: 39721217 Free article.
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).
Boada M, Neve A, Das B, Wojtowicz J, Huang Z, Bullain S, Watkin M, Lott D, Bittner T, Delmar P, Klein G, Hofmann C, Kerchner GA, Smith J, Baudler M, Fontoura P, Doody RS. Boada M, et al. Among authors: doody rs. J Alzheimers Dis. 2024 Dec 16:13872877241303644. doi: 10.1177/13872877241303644. Online ahead of print. J Alzheimers Dis. 2024. PMID: 39686620
Amyloid-Related Imaging Abnormalities in Clinical Trials of Gantenerumab in Early Alzheimer Disease.
Salloway S, Wojtowicz J, Voyle N, Lane CA, Klein G, Lyons M, Rossomanno S, Mazzo F, Bullain S, Barkhof F, Bittner T, Schneider A, Grundman M, Aldea R, Boada M, Smith J, Doody R. Salloway S, et al. Among authors: doody r. JAMA Neurol. 2024 Nov 18:e243937. doi: 10.1001/jamaneurol.2024.3937. Online ahead of print. JAMA Neurol. 2024. PMID: 39556389 Free PMC article.
Promoting diversity in clinical trials: insights from planning the ALUMNI AD study in historically underrepresented US populations with early symptomatic Alzheimer's disease.
Wise-Brown A, Brangman SA, Henderson JN, Willis-Parker M, Monroe S, Mintzer JE, Grundman M, Smith J, Doody RS, Lin H, Assman B, Rippon GA, Gonzales R, Assunção SS. Wise-Brown A, et al. Among authors: doody rs. EClinicalMedicine. 2024 Jul 13;73:102693. doi: 10.1016/j.eclinm.2024.102693. eCollection 2024 Jul. EClinicalMedicine. 2024. PMID: 39429811 Free PMC article. Review.
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.
Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T, Simuni T, Postuma RB, Pavese N, Stocchi F, Brockmann K, Smigorski K, Gerbaldo V, Fontoura P, Doody R, Kerchner GA, Brundin P, Marek K, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: doody r. Nat Med. 2024 Dec;30(12):3669-3675. doi: 10.1038/s41591-024-03270-6. Epub 2024 Oct 8. Nat Med. 2024. PMID: 39379705 Free PMC article. Clinical Trial.
Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force.
Angioni D, Cummings J, Lansdall CJ, Middleton L, Sampaio C, Gauthier S, Cohen S, Petersen RC, Rentz DM, Wessels AM, Hendrix SB, Jessen F, Carrillo MC, Doody RS, Irizarry M, Andrews JS, Vellas B, Aisen P. Angioni D, et al. Among authors: doody rs. J Prev Alzheimers Dis. 2024;11(5):1219-1227. doi: 10.14283/jpad.2024.112. J Prev Alzheimers Dis. 2024. PMID: 39350367
512 results